EpithalonvsVentfort

Molecular Formula

C₁₄H₂₂N₄O₉

Molecular Weight

390.35 g/mol

Half-Life

2-4 hours (estimated)

Bioavailability

High when injected subcutaneously

CAS Number

307297-39-8

Molecular Formula

Complex peptide mixture (multiple sequences, MW range up to ₅ kDa; active component KED: C₁₃H₂₂N₄O₇)

Molecular Weight

Complex mixture up to 5,000 Da; KED active tripeptide: ~362.3 g/mol

Half-Life

Short plasma half-life typical of ultrashort peptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to vascular gene expression; metabolized to constituent amino acids

Bioavailability

Oral formulation absorbed via intestinal peptide transporters; ultrashort peptides in the complex have efficient cellular uptake; injectable form provides direct systemic delivery; tissue-derived peptides maintain bioactivity through enteric-coated capsule formulation

CAS Number

Not applicable (tissue-derived complex)

Common

• Injection site redness
• Mild headache
• Temporary fatigue

Uncommon

• Vivid dreams
• Sleep pattern changes

Serious

• Allergic reaction

Common

• Injection site reaction
• Mild fatigue
• Mild headache
• Mild blood pressure fluctuation

Uncommon

• Mild dizziness

Serious

• No documented serious adverse effects

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Two different substances share this page's name, and almost all of the human data belongs to the older one. Epithalamin is an extract of the pineal gland. Epitalon (also written Epithalon, sequence Ala-Glu-Asp-Gly) is the synthetic four-amino-acid peptide later identified within it [4]. The long-term human studies people cite for this compound used **Epithalamin, the extract** — not the synthetic peptide. Those studies report the outcomes plainly. In 266 elderly people followed 6-8 years, mortality in the Epithalamin group fell 1.6-1.8-fold against control [6]. In a separate 12-year randomised study in elderly patients with coronary disease, deaths in the epithalamine group were 28% lower than control on the same basic therapy, and cardiovascular mortality was 2-fold lower [8]. For the synthetic peptide itself, a 2025 peer-reviewed review identifies only two human uses: 5.0 micrograms per eye injected parabulbarly for 10 consecutive days in retinitis pigmentosa, and 0.5 mg per day sublingually for 20 days in a circadian rhythm study [3]. That same review states that before Epitalon could be approved as a new active ingredient, further studies of short- and long-term toxicity are essential, including genotoxicity, carcinogenic potential and food-drug interactions [3]. Reported side effects across this literature are limited to mild injection site reactions. Nearly all of it comes from one research group in Russia [3][6].

Contraindications

• xPregnancy or planning to become pregnant
• xCurrently breastfeeding
• xActive cancer or history of cancer
• xKnown allergy to peptide components
• xChildren and adolescents

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Ventfort (collagen peptide complex) demonstrates excellent safety profile from cosmetic and nutritional supplement use spanning decades. Hydrolyzed collagen peptides pass through the GI tract largely unchanged—minimal systemic absorption occurs, making serious adverse effects unlikely. Mild gastrointestinal side effects (bloating, dyspepsia) occur in <5% of users and are generally self-limiting. Allergic reactions are rare given the high molecular weight peptide fragments; histamine content is negligible in properly processed formulations.

Contraindications

• xKnown hypersensitivity to bovine-derived peptide products or any constituent amino acids
• xActive bleeding disorders or concurrent anticoagulant therapy without medical supervision
• xSevere cardiovascular disease requiring immediate medical intervention
• xPregnancy and breastfeeding — insufficient reproductive safety data